• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

VIVA 17 Round-up: Medtronic touts real-world data for In.Pact Admiral drug-coated balloon

September 12, 2017 By Sarah Faulkner

Mercator’s Bullfrog micro-infusion device tested to improve durability after femoropopliteal revascularization

Mercator MedSystemsTwo-year data from Mercator Medsystem‘s Dance trial were presented at the VIVA conference this year by Dr. George Adams. The trial provides the largest, long-term data set assessing patency rates in atherectomy patients with adjunctive local drug therapy, according to the presentation.

The study was designed to evaluate the safety and efficacy of adventitial dexamethasone delivery, via Mercator’s Bullfrog micro-infusion device, to improve durability after femoropopliteal revascularization.

The Dance trial’s atherectomy subgroup included 157 limbs, according to the research team, and participants were eligible for the study if they had lesions in the femoral and/or popliteal arteries up to 15 centimeters in length, as well as Rutherford 2-4 peripheral artery disease.

Atherectomy methods included directional, rotational, laser and front-cutting, the team said, and stenting didn’t prevent subjects from enrolling in the trial.

The Bullfrog micro-infusion device delivered dexamethasone sodium phosphate with 20% contrast medium after atherectomy and prior to any stenting. Researchers followed up with patients after 6, 12, 18 and 24 months.

Primary patency was determined by lack of binary restenosis or clinically driven target lesion revascularization. The preliminary two-year primary patency rate was 72.8% and freedom from CD-TLR was 85.2%.

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: acotecscientific, C.R. Bard, cook medical, Medtronic, Mercator MedSystems, Royal Philips, SurModics Inc.

IN CASE YOU MISSED IT

  • EmblemHealth to provide coverage for Senseonics’ Eversense CGM
  • Eitan Medical lands FDA clearance for infusion pump system upgrade
  • Senseonics announces $50M from stock offering
  • BD stock up on Street-beating preliminary quarterly revenue numbers
  • Locate Bio lands FDA breakthrough nod for bone infection device

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS